BioCentury-BayHelix China Healthcare Summit Schedule

The BioCentury-BayHelix China Healthcare Summit, launched in 2014 in Shanghai, is the place to pressure test your cross-border strategy and build C-level relationships.
Schedule subject to change.

Schedule

Timezone:
Asia/Singapore/Shanghai
General Registration & Networking
8:00 AM - 9:00 AM (Asia/Singapore/Shanghai)
Welcome Remarks – Day 1
9:00 AM - 9:15 AM (Asia/Singapore/Shanghai)

David Flores
Co-Founder, President & CEO
BioCentury Inc.
Guo-Liang Yu, Ph.D.
former Chairman, BayHelix and
Chairman & CEO, Apollomics Inc.
C-level Partnering Meetings
9:00 AM - 5:00 PM (Asia/Singapore/Shanghai)

Presenting Company Presentations
9:00 AM - 4:15 PM (Asia/Singapore/Shanghai)

GENE & CELL THERAPY

9:00 AM - Kanglin Biotech Co. Ltd.

9:15 AM - Shanghai UniXell Biotechnology Co. Ltd.

CANCER

9:30 AM - MediLink Therapeutics (Suzhou) Co. Ltd.

9:45 AM - Innovent Biologics Inc.

10:00 AM - Abbisko Therapeutics Co. Ltd.

10:15 AM - Cothera Biosciences Inc.

10:30 AM - GeneQuantum Healthcare (Suzhou) Co. Ltd.

10:45 AM - DotBio Pte. Ltd.

11:00 AM - Impact Therapeutics Inc.

HOT TOPICS

11:15 AM - CBC HIP

11:30 AM - Evotec SE

siRNA THERAPEUTICS

1:00 PM - Pramomolecular GmbH

1:15 PM - SynerK Inc.

1:30 PM - Brii Biosciences Ltd.

NEUROLOGY, PSYCHIATRY & OPHTHALMOLOGY

1:45 PM - AffaMed Therapeutics (Shanghai) Co. Ltd.

2:00 PM - Aprinoia Therapeutics Inc.

2:15 PM - Zhaoke Ophthalmology Ltd.

2:30 PM - Genuv Inc.

CANCER

2:45 PM - Enterome S.A.

3:00 PM - CStone Pharmaceuticals Co. Ltd.

3:15 PM - Antengene Corp. Ltd.

3:30 PM - Overland Pharmaceuticals Inc.

3:45 PM - Laekna Inc.

HOT TOPICS

4:00 PM - Galapagos N.V.

4:15 PM - HitGen Inc.

4:30 PM - WuXi Biologics Inc.

4:45 PM - Guardant Health Inc.

5:00 PM - Zhongjing Pukang (Beijing) Pharmaceutical Technology Co. Ltd.             

BioCentury’s Scene Setter Panel : The Global Innovation Marketplace
9:15 AM - 10:00 AM (Asia/Singapore/Shanghai)

Despite global tensions, innovative assets from China are attracting deals with the West and provide China biopharmas with a path to maximize the impact of their science and technology. BioCentury's 3nd annual China Summit "Scene Setter" panel brings together industry leaders to examine what innovation strengths in China are driving the growth of cross-border dealmaking with the West.

Session Chair:
David Flores
Co-Founder, President & CEO
BioCentury Inc.
Panelists:
Ute Lehmann
VP BD & KAM
Boehringer Ingelheim Biopharmaceutical
Nisa Leung
Managing Partner
Qiming Venture Partners
Mark Lotter
Founder & CEO
Nuance Pharma
Jean-Christophe Pointeau
President, China
Pfizer Inc.
Xiaobin WU, Ph.D.
President & Chief Operating Officer
BeiGene Ltd.
Gaobo Zhou
Chief Investment Officer
Simcere Pharmaceutical Group Ltd.
Capital Markets Showcase: Preparing for the Biotech Breakout
10:00 AM - 10:45 AM (Asia/Singapore/Shanghai)

Times are tough. From the global bear market to rising geopolitical and regulatory risks, biotechs CEOs and investors are navigating an increasingly difficult financial landscape. But savvy leaders are preparing now for better times. How can you best manage down-rounds, creative financing structures, or partnerships to extend your cash runway today? Which venue will break out first, HKEX or NASDAQ? What lessons have been learned from biotechs that have raised recent follow-ons? How do biotechs manage geopolitical risks in the current climate? The China Summit's annual Capital Market Showcase again brings investors, bankers, and CEOs to share thoughtful approaches to major industry challenges.

Session Co-Chairs:
James C. Lin, D.Phil.
Partner
Davis Polk
Xuelin (Steve) Wang
Partner
Davis Polk
Panelists:
Lan Kang
Senior Managing Director
CBC Group
Samuel Thong
Chairman & Co-Head, Healthcare Investment Banking, Asia Ex-Japan
Goldman Sachs
Stella Xu, Ph.D.
Managing Partner
Quan Capital
Yu Gao
CFO
New Horizon Health
Jieyu Zou
Partner
Lilly Asia Ventures
Morning Networking Break
10:45 AM - 11:15 AM (Asia/Singapore/Shanghai)
Fireside Chat: What's Next for China's Innovators?
11:15 AM - 12:00 PM (Asia/Singapore/Shanghai)

As China innovators face new challenges, what steps must be taken to navigate the industry's first bear market, pricing pressure on innovation, and geopolitical tension? In this fireside chat, the leaders of China's two biopharma associations discuss a path forward for China innovation and cross-border collaboration.

Session Chair:
Chen Yang
Partner
Sidley Austin
Panelists:
Wei KANG
Executive Advisor
RDPAC (R&D-Based Pharmaceutical Association Committee)
Jun Song, Ph.D.
S&E, Corporate & Business Development
S&G, Novartis
Networking Lunch
12:00 PM - 1:00 PM (Asia/Singapore/Shanghai)
8th Annual R&D Roundtable: The Race to First-in-Class or Best-in-Class
1:00 PM - 1:45 PM (Asia/Singapore/Shanghai)

As China biotechs become an innovation engine for the global industry, the mandate is clear: R&D leaders must generate a portfolio of first- or best-in-class assets to land the right global partner and create value. In the Summit's 8th R&D Roundtable, "Scientist CEOs" and Heads of R&D discuss how their strategy is evolving to meet this high bar.

Session Chair:
Steve Yang, Ph.D.
Co-CEO
WuXi AppTec Co. Ltd.
Panelists:
Yongjun Liu, M.D., Ph.D.
President
Innovent Biologics
Hong Shen, Ph.D.
SVP & Head, Innovation Center China
Roche
Weiguo Su, Ph.D.
Executive Director, CEO and Chief Scientific Officer
Hutchmed
Ziye Sui, Ph.D.
CEO
Lepu
Diagnostics Showcase: The Road Ahead for Innovators
1:45 PM - 2:30 PM (Asia/Singapore/Shanghai)

As new technologies emerge and populations age in China and the West, precision medicine will increasingly rely on new and sensitive diagnostics to select or stratify patients for the right therapies. In a era of growing pricing control, how do innovators tackle the challenge of market entry and adoption, while demonstrating long-term clinical value for patients and benefits for the healthcare system.

Session Co-Chairs:
Jay Dong
CEO
UltraDx Bio
Victor Shi, Ph.D.
former Chairman, BayHelix, and
Managing Partner, Serica Partners
Panelists:
Jian-Bing Fan, Ph.D.
CEO
AnchorDx
Song Gao
Executive Director & CEO
Adicon
Claire Sha, M.D.
Managing Partner
AriMed Capital
Yiwei Tang, Ph.D.
Chief Medical Officer
Danaher Greater China
Afternoon Networking Break
2:30 PM - 3:00 PM (Asia/Singapore/Shanghai)
Exclusive Medtech Conference Report from McKinsey & Company: Value creation for China MedTech in uncertain times
3:00 PM - 3:30 PM (Asia/Singapore/Shanghai)

For its third China medtech report, Insights Partner McKinsey & Company assesses key trends in the China Medtech market and emerging models for value creation. Advanced access to McKinsey's report will be available exclusively to all China Summit delegates.

Keynote Presenter:
Jody Tian
Partner
McKinsey & Co.
China Medtech: The Emerging Innovation Ecosystem
3:30 PM - 4:15 PM (Asia/Singapore/Shanghai)

While local innovation is demonstrating unique value propositions, an increasingly challenging market environment calls for higher quality, agility, and industry collaborations to merge complementary capabilities. Leading medtech multinationals also play a critical role in upgrading the innovation ecosystem. In this panel discussion, industry leaders and investors discuss the path forward for medtech partnerships and emerging investment opportunities.

Session Co-Chairs:
Kevin Wu, Ph.D.
Partner
McKinsey & Company
Panelist:
Shirley Xu
President, Baxter (China) Holding Ltd.
Baxter Healthcare
Yonghui Shi, Ph.D.
SVP, Chief Strategy & Corporate Development Officer
MicroTech Medical
Alex Ng, M.D.
President
Tencent Healthcare
Troy Chen
Managing Director
Hillhouse
China Biotech Strategy: How to Make MRCTs Work
4:15 PM - 5:00 PM (Asia/Singapore/Shanghai)

Regulators everywhere are aligned: Multiregional clinical trials are required for approval in key markets. As China biotechs look to globalize, they must chart a path to clinical trials in the U.S. and Europe. In this session, industry KOLs discuss how to generate data and accelerate development via a global strategy.

Session Chair:
Dan Zhang, M.D.
Co-Chairman
Hillgene
Panelists:
Jing He, M.D., Ph.D.
SVP & Head, China R&D
AstraZeneca plc
Joan Shen, M.D., Ph.D.
Founder & CEO
NeuShen Therapeutics
Yu Tang, M.D.
Executive Director, Clinical Trial Center
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lianshan Zhang, Ph.D.
President, Global R&D
Jiangsu Hengrui Medicine Co. Ltd.
Chouwen Zhu, M.D.
President
Shanghai Clinical Research and Trial Center
Biotech Fireside Chat - Past and Future: China's place in the global innovation narrative
5:00 PM - 5:30 PM (Asia/Singapore/Shanghai)

For more than 40 years, Dr. Samuel Waksal, Chairman and CEO of Graviton Biosciences, has been founding biotech companies, ranging from ImClone to Kadmon, finding billion-dollar drugs, including Erbitux and Cyramza, and achieving multi-billion-dollar exits to buyers like Bristol-Myers and Sanofi. Graviton has found innovation for its ROCK2 platform in China, obtaining ex-China rights to GV101 from Beijing Tide Pharmaceutical in 2021. And alumni from Waksal's many ventures have become biopharma leaders in China. To close the first day of the Summit, Dr. Waksal reflects on the closing of the innovation gap between China and the West and what he expects to see in the future.

Samuel Waksal, Ph.D.
Chairman & CEO
Graviton Bioscience
10th Annual China Healthcare Summit Networking Reception
5:30 PM - 6:30 PM (Asia/Singapore/Shanghai)
10th Annual China Healthcare Summit & Gala Celebration
6:30 PM - 9:00 PM (Asia/Singapore/Shanghai)